Report: China Life invests US $42.4m in Series B round for Yingke Biopharmaceutic

Yingke was established in 2022 and is engaged in the R&D of pharmaceutical drugs

Share

Report china life invests us 4m in series b round for yingke biopharmaceutic
Picture of Editorial team

Editorial team

THIS PREMIUM INSIGHT IS FOR SUBSCRIBERS ONLY.

Stay ahead with precise, independent journalism of APAC's insurance markets.

Unlocked access today:

Already subscribed? Log in using the form below or click here

Read next

iccsc-unveils-new-action-plan-to-help-build-trust-in-singapores-insurance-sector
ageing-workforce-demands-employees-comp-rethink
beazleys-new-apac-head-looks-to-strong-growth-in-cyber-property-and-marine
singapore-life-industry-sees-strong-premium-growth-through-first-three-quarters-of-2024
gen-z-demongraphic-shift-highlights-need-for-flexible-insurance-products
sirc-2024-reflections-living-in-a-world-of-accelerated-risk
asia-insurtech-funding-falls-with-global-investment-expected-to-stabilise-at-us4-2bn-in-2024
what-the-us-election-result-means-for-asias-insurance-markets
industry-needs-to-adapt-and-reshape-image-to-attract-young-talent-canopius-report
1-1-renewals-reinsurers-stay-selective-as-buyers-market-emerges

Share this article